Royal Bank Of Canada Issues Positive Forecast for Exelixis (NASDAQ:EXEL) Stock Price

Exelixis (NASDAQ:EXEL) had its price objective increased by analysts at Royal Bank Of Canada from $45.00 to $46.00 in a research note issued on Wednesday,Benzinga reports. The brokerage currently has a “sector perform” rating on the biotechnology company’s stock. Royal Bank Of Canada’s target price would indicate a potential upside of 9.34% from the stock’s current price.

Several other research firms have also commented on EXEL. UBS Group set a $41.00 price target on shares of Exelixis in a report on Monday, January 5th. Stifel Nicolaus lifted their target price on shares of Exelixis from $43.00 to $44.00 and gave the company a “hold” rating in a report on Wednesday. Weiss Ratings reiterated a “buy (b)” rating on shares of Exelixis in a report on Thursday, January 22nd. Citigroup cut Exelixis from a “market outperform” rating to an “underperform” rating in a research note on Monday, January 5th. Finally, Wolfe Research began coverage on Exelixis in a report on Tuesday, November 18th. They set a “peer perform” rating on the stock. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $46.53.

Exelixis Stock Down 2.1%

Shares of EXEL stock traded down $0.91 on Wednesday, reaching $42.07. 1,741,698 shares of the stock were exchanged, compared to its average volume of 2,572,806. The stock has a market cap of $11.28 billion, a P/E ratio of 17.78, a price-to-earnings-growth ratio of 0.74 and a beta of 0.42. The firm has a 50 day moving average of $43.69 and a two-hundred day moving average of $40.92. Exelixis has a 1-year low of $32.38 and a 1-year high of $49.62.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.20. The firm had revenue of $598.66 million during the quarter, compared to the consensus estimate of $609.17 million. Exelixis had a return on equity of 31.06% and a net margin of 29.63%.The firm’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.55 earnings per share. On average, equities research analysts predict that Exelixis will post 2.04 EPS for the current fiscal year.

Insider Buying and Selling at Exelixis

In other Exelixis news, EVP Patrick J. Haley sold 34,187 shares of the firm’s stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $41.88, for a total value of $1,431,751.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last ninety days, insiders sold 72,230 shares of company stock worth $3,046,923. 2.85% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Exelixis

Several institutional investors have recently bought and sold shares of the business. Richardson Financial Services Inc. grew its stake in shares of Exelixis by 95.1% during the third quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 292 shares during the last quarter. Anchor Investment Management LLC raised its position in shares of Exelixis by 500.0% during the third quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 500 shares during the last quarter. Root Financial Partners LLC acquired a new position in shares of Exelixis during the third quarter valued at $28,000. Luminist Capital LLC increased its position in Exelixis by 2,740.0% in the second quarter. Luminist Capital LLC now owns 710 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 685 shares during the period. Finally, Activest Wealth Management bought a new stake in Exelixis during the 4th quarter worth about $32,000. Institutional investors own 85.27% of the company’s stock.

Key Stories Impacting Exelixis

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Q4 EPS materially beat estimates (reported $0.94 vs. ~$0.74 consensus) and operating profit/net income improved, supporting near‑term profitability and cash generation. Zacks: Q4 Earnings Beat
• Positive Sentiment: Management authorized and executed substantial buybacks (~$264.5M reported), returning capital while keeping R&D investment high — a mix that can support shareholder value and signal confidence in the pipeline. MarketBeat: Solid Earnings & Buybacks
• Positive Sentiment: Commercial momentum: the Cabometyx franchise remains the primary revenue driver (multi‑indication use), with the franchise cited at ~$2.12B and ongoing sales expansion supporting 2026 revenue guidance. MSN: Cabometyx Franchise & Growth Strategy
• Positive Sentiment: Pipeline catalyst: zanzalintinib is advancing toward regulatory review/launch plans (potential multi‑billion peak sales) — a successful approval would materially change the growth profile. Zacks: Zanzalintinib in Focus
• Neutral Sentiment: 2026 revenue guidance ($2.52–$2.62B) was reiterated but explicitly excludes potential zanzalintinib contribution — guidance gives a concrete baseline but leaves upside conditional on approval. BusinessWire: Q4 Results & Guidance
• Neutral Sentiment: Investors can review the earnings call transcript and slide deck for detail on commercialization and R&D pacing; management emphasizes a franchise strategy and continued ~ $1B R&D investment. Seeking Alpha: Earnings Call Transcript
• Negative Sentiment: Total revenue missed Street estimates (reported ~$598.7M vs. consensus ~ $609–616M), which helps explain the share pullback despite the EPS beat. QuiverQuant: Revenue Miss
• Negative Sentiment: Mixed analyst signals: some firms reiterated/raised targets but Wells Fargo’s updated Equal Weight target ($35) implies downside vs. the market price — adding near‑term pressure from cautious forecasts. TickerReport: Wells Fargo PT Raised to $35
• Negative Sentiment: Recent insider selling noted in filings (several executive sales highlighted), which can be interpreted negatively by some investors even as other insiders made purchases. QuiverQuant: Insider Activity Summary

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.